Progress of targeting PI3K-AKT-mTOR signaling pathway inhibitors in treatment of triple-negative breast cancer / 肿瘤研究与临床

ABSTRACT

Triple-negative breast cancer (TNBC) is a subtype of breast cancer, which has the biological characteristics of high invasiveness, early recurrence, rapid progression and easy invasion. Current studies have demonstrated that abnormal activation of the PI3K-AKT-mTOR signaling pathway is more common in TNBC. This article reviews the abnormal activation mechanism of PI3K-AKT-mTOR signaling pathway, related clinical progress and the application of related targeted inhibitors to provide more approaches for investigational therapies in TNBC.